| QTcN mean change from baseline: ΔQTcN (ms) | Difference from placebo: ΔΔQTcN (ms) | HR mean change from baseline: ΔHR (bpm) | Difference from placebo: ΔΔHR (bpm) | |||
---|---|---|---|---|---|---|---|
Treatment | n | Adjusted mean (SE) | Adjusted mean (SE) | 90% CI (lower, upper) | Adjusted mean (SE) | Adjusted mean (SE) | 90% CI (lower, upper) |
Placebo | 29 | 3.7 (1.0) | 0.6 (0.8) | (-0.7, 1.9) | -0.3 (0.4) | -0.9 (0.5) | (-1.8, 0.0) |
Empagliflozin 25Â mg | 28 | 4.3 (1.1) | Â | Â | -1.2 (0.5) | Â | Â |
Placebo | 29 | 3.7 (0.9) | -0.2 (0.7) | (-1.4, 0.9) | -0.3 (0.4) | 0.0 (0.5) | (-0.9, 0.8) |
Empagliflozin 200Â mg | 30 | 3.4 (0.9) | Â | Â | -0.3 (0.5) | Â | Â |
Placebo | 29 | 3.5 (1.1) | 12.4 (1.0) | (10.7, 14.1) | -0.2 (0.4) | 2.2 (0.6) | (1.1, 3.3) |
Moxifloxacin 400Â mg | 29 | 16.0 (1.2) | Â | Â | 2.0 (0.6) | Â | Â |